Business, energy, technology, markets and global industry news from Business News Today

ALK-positive NSCLC

PharmaDeviceNews ALK-positive NSCLC
Representative image: GSK’s $10.6 billion Nuvalent deal puts precision lung cancer therapies in focus as Big Pharma races to secure late-stage oncology assets.
Pharma & Biotech

Why GSK is paying $10.6bn for Nuvalent as targeted lung cancer drugs near FDA decisions

GSK is betting $10.6B on Nuvalent’s lung cancer drugs. The payoff now depends on FDA decisions, labels and oncology launch execution.

Read More
Representative image of an oncology consultation involving lung scan review, reflecting how Xcovery Holdings’ Ensacove launch and EVERSANA’s commercialization support could influence patient access in ALK-positive non-small cell lung cancer care.
Pharma & Biotech

Can EVERSANA help Xcovery turn Ensacove into a serious ALK-positive lung cancer contender?

ALK lung cancer has strong therapies already. Xcovery’s Ensacove now faces the harder test of access, adoption, and differentiation.

Read More